Table 1

Baseline characteristics and outcomes for each study included in the meta-analysis

First author, year (ref.)Study duration (week)SUNComparatorNStroke
(SU/C, n)Race (SU/C, % of white)Sex (SU/C, % of male)MeanAdjudication (Yes/No)
Age (SU/C, year)Diabetes duration (SU/C, year)HbA1c (SU/C, %)BMI (SU/C, kg/m2)
BaselineEnd point
Arechavaleta 2011 (52)30Glimepiride + metformin519Sitagliptin + metformin5162/057.4/57.653.8/55.056.2/56.36.7/6.87.5/7.57.1/7.030.2/29.7No
Bakris 2006 (53)32Glyburide + metformin180Rosiglitazone + metformin1941/076.0/78.069.0/63.058.8/60.07.6/8.08.3/8.374/7.831.8/31.6No
Charbonnel 2005 (54)52Gliclazide + metformin313Pioglitazone + metformin3173/2NR/NR49.2/50.857.0/56.05.5/5.88.5/8.77.9/7.832.6/32.6No
Ferrannini 2009 (55)52Glimepiride1,393Vildagliptin1,3967/085.2/86.354.1/52.857.5/57.55.8/5.77.3/7.36.6/6.831.7/31.8Yes
Gallwitz 2012 (56)104Glimepiride775Linagliptin77611/385.0/85.061.0/60.059.8/59.8NR/NR7.7/7.77.3/7.530.3/30.2Yes
Gerstein 2010 (57)78Glipizide339Rosiglitazone3331/5NR/NR65.8/70.060.2/61.84.6/5.07.2/7.17.0/6.829.8/29.3Yes
Göke 2010 (58)52Glipizide + metformin430Saxagliptin + metformin4281/084.2/82.254.0/49.557.6/57.55.4/5.57.7/7.76.7/6.731.3/31.5No
Home 2009 (59)286SU + metformin1,105Rosiglitazone + metformin1,11732/2598.4/98.952.9/53.857.2/57.06.3/6.17.8/7.87.7/7.532.7/32.8Yes
Hong 2013 (60)156Glipizide148Metformin15615/10NR/NR77.0/78.263.8/62.85.6/5.67.6/7.67.1/7.025.1/25.2Yes
Kahn 2006 (61)260Glyburide1,441Rosiglitazone1,45617/1689.0/87.258.0/55.756.4/56.3NR/NR7.4/7.47.6/7.132.2/32.2Yes
Glyburide1,441Metformin1,45417/1989.0/89.158.0/59.456.4/57.9NR/NR7.4/7.47.6/7.332.2/32.1
Matthews 2005 (62)52Gliclazide313Pioglitazone3175/4100.0/99.449.2/50.857.0/56.05.5/5.88.5/8.77.3/7.232.6/32.6No
Mazzone 2006 (63)72Glimepiride228Pioglitazone2300/165.4/59.662.7/63.559.9/59.37.5/8.07.4/7.47.2/7.231.9/32.0Yes
Nissen 2008 (64)78Glimepiride273Pioglitazone2701/080.6/83.365.9/68.959.7/60.05.9/5.87.4/7.47.0/6.932.0/32.1Yes
Riddle 1998 (65)78Glimepiride + insulin72Placebo + insulin731/057.0/58.062.5/54.858.0/58.07.0/7.09.7/9.97.6/7.732.2/33.7Yes
Sullivan 2011 (66)260SU1,632Metformin1,74659/4591.0/94.0NR/NR63.6/61.15.0/3.06.7/6.7NR/NR28.0/31.0No
SU1,632Diet2,62759/6391.0/95.0NR/NR63.6/62.25.0/2.06.7/6.0NR/NR28.0/29.0No
Tolman 2009 (67)156Glibenclamide1,046Pioglitazone1,0519/1062.1/59.855.5/57.255.0/54.05.6/5.99.5/9.5NR/NR32.5/32.5No
UKPDS 1998 (68)577Chlorpropamide619Insulin91133/4279.0/82.058.0/72.054.0/54.0NR/NR6.3/6.17.8/7.827.0/27.0Yes
Chlorpropamide619Diet89633/4779.0/83.058.0/61.954.0/54.0NR/NR6.3/6.27.8/8.627.0/27.5
Glibenclamide615Insulin91145/4284.0/82.061.9/72.054.0/54.0NR/NR6.3/6.18.4/7.827.4/27.0
Glibenclamide615Diet89645/4784.0/83.061.9/61.954.0/54.0NR/NR6.3/6.28.4/8.627.4/27.5
  • Relevant data included the first author’s name, year of publication, follow-up duration, characteristics of the study population (race, sex, mean age, mean duration of diabetes, mean BMI, and initial mean HbA1c). The number of events for the morbidity of stroke was also abstracted. If similar studies were reported in more than one publication, we extracted data from the most recent article. Studies were excluded if the search terms used in the search strategies were not contained in the abstract (filtered using RefWorks). All of the information was summarized in a standardized data extraction table. C, comparator; NR, not reported; SU, sulfonylurea.